BR112012014486A2 - derivados de aril triazol heteroaromático como inibidaores de enzima pde10a - Google Patents

derivados de aril triazol heteroaromático como inibidaores de enzima pde10a

Info

Publication number
BR112012014486A2
BR112012014486A2 BR112012014486A BR112012014486A BR112012014486A2 BR 112012014486 A2 BR112012014486 A2 BR 112012014486A2 BR 112012014486 A BR112012014486 A BR 112012014486A BR 112012014486 A BR112012014486 A BR 112012014486A BR 112012014486 A2 BR112012014486 A2 BR 112012014486A2
Authority
BR
Brazil
Prior art keywords
formula
enzyme inhibitors
subject
compound
effective amount
Prior art date
Application number
BR112012014486A
Other languages
English (en)
Inventor
Püschl Ask
Nielsen Jacob
Kehler Jan
Paul Kilburn John
Marigo Mauro
Langgard Morten
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of BR112012014486A2 publication Critical patent/BR112012014486A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Abstract

derivados de aril triazol heteroaromático como inibidores de enzima pde10a esta invenção é dirigida aos compostos (fórmula 1), que são inibidores de enzima pde10a. a invenção fornece uma composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz de um composto da invenção e um portador farmaceuticamente aceitável. a presente invenção também fornece processos para a perparação dos compostos da fórmula (i). a presente invenção fornece ainda um método de tratar um indivíduo que sofre de um transtorno neurodegenerativo compreendendo administrar ao indivíduo uma quantidade terapeuticamente eficaz de um composto da fórmula (i). a presente invenção também fornece um método de tratar um indivíduo que sofre de um vício compreendendo administrar ao invidíduo uma quantidade terapeuticamente eficaz de um composto da fórmula (i). a presente invenção fornece ainda um método de tratar um indivíduo que sofre de um transtorno psiquiátrico compreendendo administrar ao indivíduo uma quantidade terapeuticamente eficaz de um composto da fórmula (i).
BR112012014486A 2009-12-17 2010-12-15 derivados de aril triazol heteroaromático como inibidaores de enzima pde10a BR112012014486A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200901340 2009-12-17
PCT/DK2010/050344 WO2011072697A1 (en) 2009-12-17 2010-12-15 Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors

Publications (1)

Publication Number Publication Date
BR112012014486A2 true BR112012014486A2 (pt) 2017-04-04

Family

ID=44246811

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012014486A BR112012014486A2 (pt) 2009-12-17 2010-12-15 derivados de aril triazol heteroaromático como inibidaores de enzima pde10a

Country Status (36)

Country Link
US (2) US8501795B2 (pt)
EP (1) EP2513106B1 (pt)
JP (1) JP6035149B2 (pt)
KR (1) KR101779629B1 (pt)
CN (1) CN102753550B (pt)
AR (1) AR079496A1 (pt)
AU (1) AU2010333438B2 (pt)
BR (1) BR112012014486A2 (pt)
CA (1) CA2783728C (pt)
CO (1) CO6602117A2 (pt)
CR (1) CR20120318A (pt)
CY (1) CY1116361T1 (pt)
DK (1) DK2513106T3 (pt)
DO (1) DOP2012000169A (pt)
EA (1) EA021606B1 (pt)
ES (1) ES2442179T3 (pt)
GE (1) GEP20146201B (pt)
GT (1) GT201200193A (pt)
HK (1) HK1177745A1 (pt)
HR (1) HRP20131210T1 (pt)
IL (1) IL220328A (pt)
MA (1) MA33923B1 (pt)
MX (1) MX2012006715A (pt)
MY (1) MY156520A (pt)
NZ (1) NZ600365A (pt)
PL (1) PL2513106T3 (pt)
PT (1) PT2513106E (pt)
RS (1) RS53101B (pt)
SG (1) SG181672A1 (pt)
SI (1) SI2513106T1 (pt)
SM (1) SMT201400009B (pt)
TN (1) TN2012000278A1 (pt)
TW (1) TWI487705B (pt)
UA (1) UA107950C2 (pt)
WO (1) WO2011072697A1 (pt)
ZA (1) ZA201204420B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為pde10a酵素抑制劑的2-芳基咪唑衍生物
TWI487705B (zh) * 2009-12-17 2015-06-11 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
SG192839A1 (en) 2011-02-18 2013-09-30 Allergan Inc Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
KR101584925B1 (ko) * 2011-09-19 2016-01-12 에프. 호프만-라 로슈 아게 Pde10a 억제제로서의 트라이아졸로피리딘 화합물
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
EA201492069A1 (ru) 2012-05-30 2015-03-31 Ф.Хоффманн-Ля Рош Аг Соединения триазола в качестве ингибиторов фосфодиэстеразы 10 (pde10)
AU2013277258B2 (en) * 2012-06-19 2017-12-07 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
EP2919781B1 (en) 2012-11-15 2017-06-28 Merck Sharp & Dohme Corp. Cyclobutyl benzimidazoles as pde10 inhibitors
JP2017501135A (ja) * 2013-11-28 2017-01-12 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft イミダゾール誘導体
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CN114671874B (zh) * 2021-08-30 2024-02-02 济南爱思医药科技有限公司 一种具有抗肿瘤活性的茶碱乙酸衍生物及其制备方法与应用
WO2023064458A1 (en) * 2021-10-13 2023-04-20 Yale University Selective jak2 inhibitors and methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1462521A (en) 1974-02-11 1977-01-26 Wyeth John & Brother Ltd Triazole derivatives
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
US6699853B2 (en) 1997-06-16 2004-03-02 Hoechst Schering Agrevo Gmbh 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides
SE9802937D0 (sv) 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
FR2824065A1 (fr) 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
ES2315546T3 (es) 2002-10-30 2009-04-01 Via Pharmaceuticals, Inc. Inhibidores delas fosfodiesterasas de los nucleotidos ciclicos, que presentan una estructura de benzodiazepina, y su uso en terapia.
AU2004253690B2 (en) 2003-06-30 2010-03-25 Nycomed Gmbh Pyrrolodihydroisoquinolines as PDE10 inhibitors
ES2331519T3 (es) 2003-06-30 2010-01-07 Nycomed Gmbh Derivados de pirrolo-dihidroisoquinolina como inhibidores de pde10.
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
BRPI0507839A (pt) 2004-02-18 2007-05-08 Pfizer Prod Inc derivados tetraidroisoquinolinil de quinazolina e isoquinolina
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
WO2005120514A1 (en) 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
CA2578996A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
EP2057153B1 (en) * 2006-07-10 2012-09-12 H. Lundbeck A/S (3-aryl-piperazin-1-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
GB0800411D0 (en) 2008-01-10 2008-02-20 Glaxo Group Ltd Novel compounds
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為pde10a酵素抑制劑的2-芳基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物
AU2011258217B2 (en) * 2010-05-26 2016-12-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof

Also Published As

Publication number Publication date
ZA201204420B (en) 2013-09-25
KR101779629B1 (ko) 2017-09-18
HRP20131210T1 (hr) 2014-01-17
DK2513106T3 (da) 2014-01-13
SG181672A1 (en) 2012-07-30
PT2513106E (pt) 2014-01-20
KR20120113215A (ko) 2012-10-12
MA33923B1 (fr) 2013-01-02
TWI487705B (zh) 2015-06-11
PL2513106T3 (pl) 2014-09-30
JP6035149B2 (ja) 2016-11-30
CY1116361T1 (el) 2017-02-08
RS53101B (en) 2014-06-30
EA201290517A1 (ru) 2012-12-28
US20130281459A1 (en) 2013-10-24
AU2010333438B2 (en) 2016-03-10
TN2012000278A1 (en) 2013-12-12
CA2783728A1 (en) 2011-06-23
TW201130834A (en) 2011-09-16
CA2783728C (en) 2018-06-12
SMT201400009B (it) 2014-03-07
MY156520A (en) 2016-02-26
US8501795B2 (en) 2013-08-06
EP2513106A1 (en) 2012-10-24
EA021606B1 (ru) 2015-07-30
JP2013514286A (ja) 2013-04-25
US8785653B2 (en) 2014-07-22
GEP20146201B (en) 2014-11-25
IL220328A0 (en) 2012-08-30
CN102753550B (zh) 2015-03-25
SI2513106T1 (sl) 2014-01-31
MX2012006715A (es) 2012-07-03
EP2513106B1 (en) 2013-11-06
ES2442179T3 (es) 2014-02-10
AU2010333438A1 (en) 2012-06-21
HK1177745A1 (en) 2013-08-30
WO2011072697A1 (en) 2011-06-23
NZ600365A (en) 2013-10-25
CR20120318A (es) 2012-08-16
IL220328A (en) 2014-12-31
US20120309764A1 (en) 2012-12-06
UA107950C2 (en) 2015-03-10
DOP2012000169A (es) 2012-12-15
GT201200193A (es) 2013-09-26
CN102753550A (zh) 2012-10-24
AR079496A1 (es) 2012-02-01
CO6602117A2 (es) 2013-01-18

Similar Documents

Publication Publication Date Title
BR112012014486A2 (pt) derivados de aril triazol heteroaromático como inibidaores de enzima pde10a
BRPI0915383B8 (pt) composto derivado de fenilimidazol e sua composição farmacêutica.
BR112015007731A2 (pt) pde9i com cadeia principal de imidazo pirazinona
TN2012000287A1 (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
UA102693C2 (ru) Производные фенилимидазола как ингибиторы фермента pde10a
TN2012000271A1 (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
JO3089B1 (ar) مشتقات ايميدازول كمثبطات لانزيمات pde10a
PH12014501695B1 (en) Pde9 inhibitors with imidazo triazinone backbone
GEP20146202B (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
MX336915B (es) Derivados de imidazol como inhibidores de la enzima pde10a.
CY1116689T1 (el) Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a
TN2013000200A1 (en) Imidazole derivatives as pde 10a enzyme inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]